A Study to Identify Breast Cancer (IDBC)

Breast Cancer Female Clinical Trial

— IDBC  

Official title:

Investigation of a Novel Blood Test to Identify Breast Cancer (IDBC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04495244
• Other study ID #: 241391
• Status: Recruiting
• Start date: January 24, 2019
• Est. completion date: December 31, 2022

Study information

• Verified date: July 2020
• Source: Syantra Inc.
• Contact: Hayley Brooks
• Phone: 0161 291 4045
• Email: Hayley.brooks[@]mft.nhs.uk
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Detecting cancer as early as possible is key to achieving positive outcomes in response to diagnosis and treatment. The current project is aimed at validating a novel blood-based breast cancer identification test (Syantra DX Breast Cancer) that has been developed by Syantra Inc. Syantra DX Breast Cancer measures gene expression signatures in whole blood, and has been retrospectively demonstrated in 780 samples. The test uses proprietary algorithms to analyse gene expression characteristics from a novel multi-biomarker panel, and then classify a sample as positive or negative for breast cancer. Based upon test performance in a retrospective environment, a prospective validation study is being proposed.

The primary objective of this study is to validate Syantra DX Breast Cancer methodology and biomarker panel using prospective samples, well categorized by diagnostic imaging scores, pathology outcomes, and subject characteristics.

Description:

The current project is aimed at validating Syantra DX Breast Cancer in a UK population. Results of the UK study will be combined with those from additional sites, including those in Canada, with additional samples expected from the United States and South Korea. Syantra DX Breast Cancer measures gene expression signatures in whole blood, and has been retrospectively demonstrated in 780 samples. The test uses proprietary algorithms to analyse gene expression characteristics from a novel multi-biomarker panel, and then classify a sample as positive or negative for breast cancer. Based upon test performance in a retrospective environment, a prospective validation study is being proposed, and is described below.

The study seeks to evaluate performance of Syantra DX Breast Cancer in prospective samples and to optimize test methodology and biomarkers. Key to performance of the study is recruitment of women who have received an abnormal mammography report, and have been classified under the UK Royal College of Radiologists Breast Group (RCRBG) scoring system in categories 3 - 5. This will support the ability to employ the test for breast cancer detection in a screening/call-back environment. To complete the study cohort, additional women will be recruited from the population who have normal or benign mammography results (RCRBG category 1 and 2), and/or a recent normal physical breast exam, with no history of breast cancer. Blood samples will be acquired from all women following completion of an informed consent procedure.

For those with an abnormal mammogram, blood will be drawn before a biopsy is performed. All sample information will be de-identified, and the samples will be processed and analysed according to Syantra DX Breast Cancer standard operating procedures. These procedures include extracting sample RNA and aliquoting for storage in a manner that maintains sample anonymity. All processing and analysis will be conducted in a blind environment without knowing the associated RCRBG or pathology outcomes for any samples. Only after testing is complete will sample classifications be revealed. Syantra DX Breast Cancer results will then be compared to RCRBG, biopsy and pathology data to determine concordance, and statistics will be calculated. If or when biomarker panel or test methodology is modified during the performance of the study, samples will be reanalysed with updated test parameters. This reanalysis will make use of a de-identified aliquot of sample RNA to ensure that testing is maintained in a blind environment.

There is an optional part of the study procedure that is included as 'additional research'. A specific question seeking approval for the additional research is included on the study consent form. For individuals who agree to participate in the additional research, material extracted from their blood sample will be stored for additional investigations.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 30 Years to 75 Years

Eligibility

Inclusion criteria

• Aged 30-75 years

• Normal breast examination - No cancer detected/suspected by physical exam, diagnostic radiology or screening mammography

• Women with suspected Invasive Breast Cancer

• Individuals with an abnormal or suspicious mammogram

• Abnormal screening mammogram with suspected benign breast disease or proliferative changes

Exclusion criteria

• Cancer diagnosis

• Male

• Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)

• Previous history of any cancer

• Concomitant or other concurrent anti-cancer therapy

• Inoperable or inflammatory breast cancer

Related Conditions & MeSH terms

• Breast Cancer Female
• Breast Neoplasms

Intervention

Diagnostic Test:
• Syantra DX Breast Cancer
Blood test for detecting the presence of breast cancer.

Locations

Country	Name	City	State
United Kingdom	Wythenshawe Hospital, Southmoor Road	Manchester

Sponsors (1)

Lead Sponsor	Collaborator
Syantra Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Performance of the Syantra DX Breast Cancer test as assessed by sensitivity and specificity	The number of participants that test positive or negative for breast cancer with the Syantra DX Breast Cancer test and their breast cancer status as assessed by mammography or pathology.	through completion of the study, approximately eighteen months
Secondary	Modulate test methodology to account for differences between retrospective and prospective samples	Determine the sensitivity and specificity of the assay with biomarker panel modifications.	through completion of the study, approximately eighteen months
Secondary	Performance of the Syantra DX Breast Cancer test in prediction of molecular subtype of breast cancer as assessed by pathology	Correlate the performance of the test to molecular characterizations of identified cancers as assessed by pathology of tissue from biopsy or resection.	through completion of the study, approximately eighteen months